PAH and phenylketonuria: Furthermore, Baruteau et al. [65] demonstrated high l-phenylalanine hydroxylase (PAH) expression and a marked increase in PAH activity in differentiated LHMSCs, suggesting therapeutic potential for phenylketonuria.